BMS-1166
BMS-1166 (CAS 1818314-88-3) is a small-molecule immune checkpoint inhibitor, functioning as a potent antagonist in T cell activation and exhibiting strong inhibitory activity against the interaction between PD-1 and its ligand PD-L1 in immune cells. Additionally, it disrupts immune checkpoint signaling pathways by inducing dimerization and thereby blocks the engagement of programmed cell death protein 1 (PD-1) with its ligand.
In in vitro experimental assays, BMS-1166 demonstrates efficient inhibition of the PD-1/PD-L1 binding with an IC50 value of 1.4 nM, tested against cellular models expressing human checkpoint proteins. It can also reverse the immune suppression mediated by the PD-1/PD-L1 axis, leading to enhanced T cell proliferation and cytokine release.
In immuno-oncology research and drug development, BMS-1166 is widely used for studying the therapeutic potential of immune checkpoint blockade, specifically focusing on antitumor immunity. Its application facilitates the evaluation of immune checkpoint-targeted strategies and accelerates preclinical investigations aimed at restoring or augmenting immune responses against cancer.
| Physical Appearance | A solid |
| Storage | -20°C |
| M.Wt | 641.11 |
| Cas No. | 1818314-88-3 |
| Formula | C36H33ClN2O7 |
| Synonyms | (4R)-1-[[5-chloro-2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]phenyl]methyl]-4-hydroxy-D-proline |
| Chemical Name | (2R,4R)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)-4-hydroxypyrrolidine-2-carboxylic acid |
| SDF | Download SDF |
| Canonical SMILES | ClC(C=C1CN2C[C@H](O)C[C@@H]2C(O)=O)=C(OCC3=CC=CC(C4=CC=C5C(OCCO5)=C4)=C3C)C=C1OCC6=CC=CC(C#N)=C6 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
